@article{FreyHoubenBroecker2010,
  author    = {Frey, Li­dia M. and Houben, Roland and Br{\"o}cker, Eva-B.},
  title     = {Pigmentation, Melanocyte Colonization, and p53 Status in Basal Cell Carcinoma},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68283},
  year      = {2010},
  abstract  = {Basal cell carcinoma (BCC) is the most common neoplasm in the Caucasian population. Only a fraction of BCC exhibits pigmentation. Lack of melanocyte colonization has been suggested to be due to p53-inactivating mutations in the BCC cells interfering with the p53-proopiomelanocortin pathway and the production of alpha melanocyte-stimulating hormone in the tumor. To evaluate this, we determined tumor pigmentation as well as expression of melan-A and of p53 in 49 BCC tissues bymeans of immunohistochemistry. As expected, we observed a positive relation between tumor pigmentation and melan-A positive intratumoral melanocytes.Melanocyte colonization and, to a lesser extent, p53 overexpression showed intraindividual heterogeneity in larger tumors. p53 overexpression, which is indicative of p53 mutations, was not correlated to melanocyte colonization of BCC. Sequencing of exon 5-8 of the p53 gene in selected BCC cases revealed that colonization by melanocytes and BCC pigmentation is neither ablated by p53 mutations nor generally present in BCCs with wild-type p53.},
  subject      = {Medizin},
  language  = {en}
}
@article{SonnenscheinvanderVoortArendsdeJongsteetal.2014,
  author    = {Sonnenschein-van der Voort, Agnes M. M. and Arends, Lidia R. and de Jongste, Johan C. and Annesi-Maesano, Isabella and Arshad, S. Hasan and Barros, Henrique and Basterrechea, Mikel and Bisgaard, Hans and Chatzi, Leda and Corpeleijn, Eva and Correia, Sofia and Craig, Leone C. and Devereux, Graham and Dogaru, Cristian and Dostal, Miroslav and Duchen, Karel and Eggesb{\o}, Merete and van der Ent, C. Kors and Fantini, Maria P. and Forastiere, Francesco and Frey, Urs and Gehring, Ulrike and Gori, Davide and van der Gugten, Anne C. and Hanke, Wojciech and Henderson, A. John and Heude, Barbara and I{\~n}iguez, Carmen and Inskip, Hazel M. and Keil, Thomas and Kelleher, Cecily C. and Kogevinas, Manolis and Kreiner-M{\o}ller, Eskil and Kuehni, Claudia E. and K{\"u}pers, Leanne K. and Lancz, Kinga and Larsen, Pernille S. and Lau, Susanne and Ludvigsson, Johnny and Mommers, Monique and Andersen, Anne-Marie Nybo and Palkovicova, Lubica and Pike, Katherine C. and Pizzi, Constanza and Polanska, Kinga and Porta, Daniela and Richiardi, Lorenzo and Roberts, Graham and Schmidt, Anne and Sram, Radim J. and Sunyer, Jordi and Thijs, Carel and Torrent, Maties and Viljoen, Karien and Wijga, Alet H. and Vrijheid, Martine and Jaddoe, Vincent W. V. and Duijts, Liesbeth},
  title     = {Preterm birth, infant weight gain, and childhood asthma risk: A meta-analysis of 147,000 European children},
  series = {The Journal of Allergy and Clinical Immunology},
  volume    = {133},
  journal   = {The Journal of Allergy and Clinical Immunology},
  number    = {5},
  doi       = {10.1016/j.jaci.2013.12.1082},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-120714},
  pages     = {1317-29},
  year      = {2014},
  abstract  = {Background Preterm birth, low birth weight, and infant catch-up growth seem associated with an increased risk of respiratory diseases in later life, but individual studies showed conflicting results. Objectives We performed an individual participant data meta-analysis for 147,252 children of 31 birth cohort studies to determine the associations of birth and infant growth characteristics with the risks of preschool wheezing (1-4 years) and school-age asthma (5-10 years). Methods First, we performed an adjusted 1-stage random-effect meta-analysis to assess the combined associations of gestational age, birth weight, and infant weight gain with childhood asthma. Second, we performed an adjusted 2-stage random-effect meta-analysis to assess the associations of preterm birth (gestational age <37 weeks) and low birth weight (<2500 g) with childhood asthma outcomes. Results Younger gestational age at birth and higher infant weight gain were independently associated with higher risks of preschool wheezing and school-age asthma (P < .05). The inverse associations of birth weight with childhood asthma were explained by gestational age at birth. Compared with term-born children with normal infant weight gain, we observed the highest risks of school-age asthma in children born preterm with high infant weight gain (odds ratio [OR], 4.47; 95\% CI, 2.58-7.76). Preterm birth was positively associated with an increased risk of preschool wheezing (pooled odds ratio [pOR], 1.34; 95\% CI, 1.25-1.43) and school-age asthma (pOR, 1.40; 95\% CI, 1.18-1.67) independent of birth weight. Weaker effect estimates were observed for the associations of low birth weight adjusted for gestational age at birth with preschool wheezing (pOR, 1.10; 95\% CI, 1.00-1.21) and school-age asthma (pOR, 1.13; 95\% CI, 1.01-1.27). Conclusion Younger gestational age at birth and higher infant weight gain were associated with childhood asthma outcomes. The associations of lower birth weight with childhood asthma were largely explained by gestational age at birth."},
  language  = {en}
}
@article{BeckerAndersenHofmeisterMuelleretal.2012,
  author    = {Becker, J{\"u}rgen C. and Andersen, Mads H. and Hofmeister-M{\"u}ller, Valeska and Wobser, Marion and Frey, Lidia and Sandig, Christiane and Walter, Steffen and Singh-Jasuja, Harpreet and K{\"a}mpgen, Eckhart and Opitz, Andreas and Zapatka, Marc and Br{\"o}cker, Eva-B. and thor Straten, Per and Schrama, David and Ugurel, Selma},
  title     = {Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma},
  series = {Cancer Immunology, Immunotherapy},
  volume    = {61},
  journal   = {Cancer Immunology, Immunotherapy},
  number    = {11},
  doi       = {10.1007/s00262-012-1266-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-126215},
  pages     = {2091-2103},
  year      = {2012},
  abstract  = {Background Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. However, many vaccination trials in melanoma failed to demonstrate a correlation between the vaccine-specific immune response and therapy outcome. This has been mainly attributed to immune escape by antigen loss, rendering us in the need of new vaccination targets. Patients and methods This phase-II trial investigated a peptide vaccination against survivin, an oncogenic inhibitor-of-apoptosis protein crucial for the survival of tumor cells, in HLA-A1/-A2/-B35-positive patients with treatment-refractory stage-IV metastatic melanoma. The study endpoints were survivin-specific T-cell reactivity (SSTR), safety, response, and survival (OS). Results Sixty-one patients (ITT) received vaccination therapy using three different regimens. 55 patients (PP) were evaluable for response and survival, and 41/55 for SSTR. Patients achieving progression arrest (CR + PR + SD) more often showed SSTRs than patients with disease progression (p = 0.0008). Patients presenting SSTRs revealed a prolonged OS (median 19.6 vs. 8.6 months; p = 0.0077); multivariate analysis demonstrated SSTR as an independent predictor of survival (p = 0.013). The induction of SSTRs was associated with gender (female vs. male; p = 0.014) and disease stage (M1a/b vs. M1c; p = 0.010), but not with patient age, HLA type, performance status, or vaccination regimen. Conclusion Survivin-specific T-cell reactivities strongly correlate with tumor response and patient survival, indicating that vaccination with survivin-derived peptides is a promising treatment strategy in melanoma.},
  language  = {en}
}
@article{BeckerAndersenHofmeisterMuelleretal.2012,
  author    = {Becker, J{\"u}rgen C. and Andersen, Mads H. and Hofmeister-M{\"u}ller, Valeska and Wobser, Marion and Frey, Lidia and Sandig, Christiane and Walter, Steffen and Singh-Jasuja, Harpreet and K{\"a}mpgen, Eckhart and Opitz, Andreas and Zapatka, Marc and Br{\"o}cker, Eva-B. and thor Straten, Per and Schrama, David and Ugurel, Selma},
  title     = {Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma},
  series = {Cancer Immunology, Immunotherapy},
  volume    = {61},
  journal   = {Cancer Immunology, Immunotherapy},
  number    = {11},
  doi       = {10.1007/s00262-012-1266-9},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-124830},
  pages     = {2091-2103},
  year      = {2012},
  abstract  = {Background Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment of melanoma. However, many vaccination trials in melanoma failed to demonstrate a correlation between the vaccine-specific immune response and therapy outcome. This has been mainly attributed to immune escape by antigen loss, rendering us in the need of new vaccination targets. Patients and methods This phase-II trial investigated a peptide vaccination against survivin, an oncogenic inhibitor-of-apoptosis protein crucial for the survival of tumor cells, in HLA-A1/-A2/-B35-positive patients with treatment-refractory stage-IV metastatic melanoma. The study endpoints were survivin-specific T-cell reactivity (SSTR), safety, response, and survival (OS). Results Sixty-one patients (ITT) received vaccination therapy using three different regimens. 55 patients (PP) were evaluable for response and survival, and 41/55 for SSTR. Patients achieving progression arrest (CR + PR + SD) more often showed SSTRs than patients with disease progression (p = 0.0008). Patients presenting SSTRs revealed a prolonged OS (median 19.6 vs. 8.6 months; p = 0.0077); multivariate analysis demonstrated SSTR as an independent predictor of survival (p = 0.013). The induction of SSTRs was associated with gender (female vs. male; p = 0.014) and disease stage (M1a/b vs. M1c; p = 0.010), but not with patient age, HLA type, performance status, or vaccination regimen. Conclusion Survivin-specific T-cell reactivities strongly correlate with tumor response and patient survival, indicating that vaccination with survivin-derived peptides is a promising treatment strategy in melanoma.},
  language  = {en}
}
@phdthesis{Frey2008,
  author    = {Frey, Lidia Marilia},
  title     = {Melanozyten in epithelialen Tumoren der Haut},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-31504},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2008},
  abstract  = {Melanozyten (MZ) sind der zweih{\"a}ufigste epidermale Zelltyp. Das Wachstum und die metabolische T{\"a}tigkeit der MZ wird durch humorale Faktoren sowie den direkten Zell-Zell Kontakt kontrolliert. Der sch{\"a}digende Einfluss der UV-Strahlung, der mit der Entwicklung von epithelialen Tumoren zusammenh{\"a}ngt, wird durch das Pigmentsystem der Haut vermindert. Im Zeitraum von Juni 2006 bis Juni 2007 wurden Pr{\"a}parate mit vorliegenden histologischen und klinischen Befunden von epithelialen Hauttumoren untersucht und mit Melanin-, Melan-A und HMB-45 gef{\"a}rbt. Hierzu geh{\"o}ren: 40 Basalzellkarzinome (BCC), 20 Plattenepithelkarzinome (PEC), 20 seborrhoische Keratosen (SK), 9 Morbi Bowen (MB), 7 aktinischen Keratosen (AK), und 5 Kerathoakantome (KA). Ziel der Arbeit war die Identifizierung und Charakterisierung der MZ in verschiedenen epithelialen Hauttumoren. Meist waren die Tumorzellen negativ in der Melaninf{\"a}rbung. Melan-A wurde am st{\"a}rksten bei SK, BCC und AK exprimiert. Im Gegensatz dazu zeigten sich bei PEC am wenigsten angef{\"a}rbten Zellen. Die HMB-45-positiv-MZ f{\"a}rbten sich am st{\"a}rksten bei AK, MB und BCC an. Obwohl HMB-45 bei allen Tumortypen positiv war, war die Ausz{\"a}hlung vom HMB-45-positiven-MZ deutlich geringer als bei Melan-A. Es gibt eine Korrelation zwischen MZ und neoplastischen Keratinozyten, jedoch ist noch nicht nachgewiesen, was die MZ dazu stimuliert, zu proliferieren und dar{\"u}ber hinaus zu kolonisieren. Eine Korrelation zwischen der epithelialen Pigmentierung und der Anzahl an MZ zeigte sich nur in gutartigen epithelialen Hauttumoren (SK), w{\"a}hrend in allen malignen Tumoren keine Korrelation zwischen der MZ-Zahl und eventueller Pigmentierung bestand. Das weist darauf hin, dass hier die Regulation der Pigmentierung zerst{\"o}rt ist.},
  subject      = {Immuncytochemie},
  language  = {de}
}